Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
|Videos|May 12, 2020
Best-Case Coronavirus Vaccine Scenarios
Author(s)Kevin Kunzmann
What is the hopeful expectation of the new candidates, relative to previously developed vaccines?
Advertisement
The future of
That puts a lot of pressure on the makeup of trial assessment—as well as understanding the maximum potential of each preventive candidate.
In an interview with Contagion, William Schaffner, MD, professor of Preventive Medicine and Medicine at the Vanderbilt University Medical Center, discussed the variability of marketed vaccines and how expectations differentiate for each disease. For example, he noted, the difference in modern protection from shingles versus influenza is significant.
And what could be hoped for in a COVID-19 vaccine?
“We would hope for something that is over 80% effective,” he said. “We have to, I think, in the 21st century, have a product that is at least 80% effective. They would hope for more, of course.”
Schaffner also discussed the stratified assessment of vaccine candidates across age groups, and the potential need of booster administrations and eventual clinical follow-up with a COVID-19 vaccine.
Advertisement
Related to this article
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement
Trending on Contagion Live
1
FAQ: Pneumonic Plague
2
Ebola Deaths Top 4,100 as Kenya Confirms First Imported Bundibugyo Case
3
Russian Lab Worker Dies in Suspected Pneumonic Plague Case
4
VAX-31 Meets Primary Endpoints in Phase 3 Pneumococcal Vaccine Study
5